The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria.
RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Is (RDHL) Outperforming Other Medical Stocks This Year?
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / RedHill Biopharma Ltd. (NASDAQ:RDHL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 27, 2020 at 8:30 AM ...
RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement.
At this time, I would like to introduce to the conference call RedHill's CEO, Mr. Dror Ben-Asher; Mr. Micha Ben Chorin, RedHill's Chief Financial Officer; Mr. Rick Scruggs, RedHill's Chief Commercial Officer; and Mr. Gilead Raday, RedHill's Chief Operating Officer. Before we begin, we will read from RedHill's safe harbor statement.
The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.
Completed acquisition of Movantik® from AstraZeneca on April 1, 2020, and initiated U.S. promotion with net revenues of $7.3 million in April--Launched commercial sales of.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. --All six analyzed.
All five patients have shown an improved CRP, with four of the five patients also demonstrating measurable clinical improvement, including required supplemental oxygenation and.
The IND submission follows preliminary discussions with the FDA on the study design. “We are moving quickly to advance the clinical development of opaganib for COVID-19 and in parallel to expand access to opaganib for patients under compassionate use to help address the global pandemic caused by SARS-CoV-2,” said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill.
With fresh data from existing trials treating COVID-19 patients in Italy and Israel, a Triangle drugmaker has announced a deal with the federal government to explore another drug as a treatment for U.S. patients.
After receiving special approval to test its drug on COVID-19 patients in Italy and Israel, a Raleigh drugmaker is reporting successful preliminary data, which suggest the drug could end up being a confirmed treatment for the pandemic.
The Company will host a conference call on Wednesday, May 27, 2020, at 8:30 a.m. EDT to review the financial results and operational highlights. The conference call will be broadcast live and available for replay for 30 days on the Company's website: http://ir.redhillbio.com/events. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.
RHB-107, an investigational new chemical entity, has been studied in more than 300 people across 10 clinical studies, including two completed Phase 2 studies in oncology patients and several Phase 1 studies in healthy volunteers and oncology patients. RHB-107 is a serine protease inhibitor active against a number of human trypsins and several other related serine proteases.
Is (RDHL) Outperforming Other Medical Stocks This Year?
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 4.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 66.67% year over year to ($0.05), which beat the estimate of ($0.24).Revenue of $1,056,000 decreased by 39.21% from the same period last year, which missed the estimate of $4,380,000.Looking Ahead Redhill Biopharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 27, 2020View more earnings on RDHLTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/cgzdt8vgTechnicals Company's 52-week high was at $9.1252-week low: $3.26Price action over last quarter: Up 51.80%Company Profile Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.See more from Benzinga * 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 17 Healthcare Stocks Moving In Friday's Pre-Market Session * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The peer-reviewed article2, entitled “Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial”, is available online and the print article is scheduled to be published in the journal’s June issue. Talicia was approved by the FDA in November 2019.